MXPA03004190A - Tratamiento de trastornos de ansiedad. - Google Patents

Tratamiento de trastornos de ansiedad.

Info

Publication number
MXPA03004190A
MXPA03004190A MXPA03004190A MXPA03004190A MXPA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A
Authority
MX
Mexico
Prior art keywords
treatment
anxiety disorders
anxiety
disorders
Prior art date
Application number
MXPA03004190A
Other languages
English (en)
Spanish (es)
Inventor
Holly Read Thomasson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA03004190A publication Critical patent/MXPA03004190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MXPA03004190A 2000-11-15 2001-11-06 Tratamiento de trastornos de ansiedad. MXPA03004190A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Publications (1)

Publication Number Publication Date
MXPA03004190A true MXPA03004190A (es) 2003-09-22

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004190A MXPA03004190A (es) 2000-11-15 2001-11-06 Tratamiento de trastornos de ansiedad.

Country Status (16)

Country Link
EP (1) EP1395253A2 (ko)
JP (1) JP2004529073A (ko)
KR (1) KR20030051812A (ko)
CN (1) CN1822825A (ko)
AU (1) AU2002217757A1 (ko)
BR (1) BR0115301A (ko)
CA (1) CA2426069A1 (ko)
CZ (1) CZ20031339A3 (ko)
EA (1) EA200300567A1 (ko)
HR (1) HRP20030384A2 (ko)
IL (1) IL155874A0 (ko)
MX (1) MXPA03004190A (ko)
NO (1) NO20032156D0 (ko)
PL (1) PL366119A1 (ko)
SK (1) SK5422003A3 (ko)
WO (1) WO2002040006A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU91038B1 (fr) * 2001-03-06 2003-09-11 Lilly Co Eli Inhibiteur d'absorption de monoamines
JP2005537307A (ja) * 2002-08-14 2005-12-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー のぼせの治療のためのレボキセチンの使用
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
CA2548304A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2009089479A2 (en) * 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US9944618B2 (en) 2013-03-14 2018-04-17 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
EA202192084A1 (ru) * 2019-02-01 2021-10-20 ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи. Композиции и способы для лечения связанных с тревожностью нарушений

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2931997A (en) * 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
ES2246485T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la incontinencia.

Also Published As

Publication number Publication date
IL155874A0 (en) 2003-12-23
CA2426069A1 (en) 2002-05-23
CN1822825A (zh) 2006-08-23
WO2002040006A2 (en) 2002-05-23
EA200300567A1 (ru) 2004-10-28
HRP20030384A2 (en) 2003-08-31
JP2004529073A (ja) 2004-09-24
EP1395253A2 (en) 2004-03-10
BR0115301A (pt) 2004-12-14
NO20032156L (no) 2003-05-13
KR20030051812A (ko) 2003-06-25
CZ20031339A3 (cs) 2003-10-15
AU2002217757A1 (en) 2002-05-27
PL366119A1 (en) 2005-01-24
SK5422003A3 (en) 2003-12-02
WO2002040006A3 (en) 2003-12-24
NO20032156D0 (no) 2003-05-13

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL159771A0 (en) Combinations for the treatment of inflammatory disorders
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
HK1048069A1 (en) Treatment of neurotic disorders.
IL155433A0 (en) Treatment of t cell disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
HK1049122A1 (en) The use of mirtazapine for the treatment of sleep disorders
IL140540A0 (en) Treatment of anxiety disorders
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
AU4838301A (en) Treatment of disorders relating to the serotonergic system
ZA200204018B (en) Combination treatment for depression and anxiety.
GB0010496D0 (en) Treatment of conditions of the central nervous system
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
GB0017951D0 (en) Treatment of movement disorders
GB0003228D0 (en) Treatment of GI disorders
GB0029955D0 (en) Treatment of neuropsychiatric disorders
GB0004998D0 (en) The treatment of functional gastrointestinal disorders
GB0021060D0 (en) Treatment of functional gastrointestinal disorders